NCT00133497View on ClinicalTrials.gov

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

PHASE2CompletedINTERVENTIONAL
Enrollment

409

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Cytomegalovirus Infections
Interventions
BIOLOGICAL

MF-59

Microfluoridized adjuvant 59 (MF59).

DRUG

Placebo

0.5 mL of saline placebo.

BIOLOGICAL

CMV gB vaccine

CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.

Trial Locations (5)

45229-3026

Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati

37232-2573

Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville

77555-1121

The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD), Galveston

77030-1501

The University of Texas Health Science Center - Pediatrics, Houston

77030-3411

Baylor College of Medicine - Molecular Virology and Microbiology, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00133497 - gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females | Biotech Hunter | Biotech Hunter